Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Inventory (2016 - 2025)

Historic Inventory for Corcept Therapeutics (CORT) over the last 10 years, with Q3 2025 value amounting to $12.3 million.

  • Corcept Therapeutics' Inventory rose 5340.37% to $12.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.3 million, marking a year-over-year increase of 5340.37%. This contributed to the annual value of $12.4 million for FY2024, which is 6056.92% up from last year.
  • As of Q3 2025, Corcept Therapeutics' Inventory stood at $12.3 million, which was up 5340.37% from $12.3 million recorded in Q2 2025.
  • In the past 5 years, Corcept Therapeutics' Inventory registered a high of $14.4 million during Q1 2025, and its lowest value of $4.7 million during Q2 2021.
  • Moreover, its 5-year median value for Inventory was $6.9 million (2023), whereas its average is $7.7 million.
  • As far as peak fluctuations go, Corcept Therapeutics' Inventory plummeted by 523.65% in 2021, and later soared by 9983.31% in 2025.
  • Corcept Therapeutics' Inventory (Quarter) stood at $5.0 million in 2021, then rose by 22.29% to $6.1 million in 2022, then grew by 26.72% to $7.7 million in 2023, then surged by 60.57% to $12.4 million in 2024, then decreased by 0.51% to $12.3 million in 2025.
  • Its last three reported values are $12.3 million in Q3 2025, $12.3 million for Q2 2025, and $14.4 million during Q1 2025.